About this episode

The episode discusses the potential use of semaglutide as a treatment for alcohol use disorder with insights from researchers.

The Lancet’s Niall Boyce and Jonathan Pimm, and eBioMedicine’s Kalypso Karastergiou discuss an exciting new potential treatment for alcohol use disorder: semaglutide. As new research is published in The Lancet, they go behind the headlines with lead author Professor Anders Fink-Jensen to ask what the study showed, and what its implications are for the future of addiction medicine. Click here to read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00305-3/fulltext

People in this episode

Hosts: Niall Boyce, Jonathan Pimm

Guest: Kalypso Karastergiou

Topics covered

• alcohol use disorder
• semaglutide
• addiction medicine
• treatment research
• health implications

Mentioned in this episode

Organizations: The Lancet, eBioMedicine

Explore listener stats, chart rankings, contacts and more on the The Lancet in conversation with podcast page.